Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New antibody duo targets advanced cancers in early trial

NCT ID NCT07158918

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 26 times

Summary

This study tests a new drug called ABL103, given with the immunotherapy pembrolizumab and sometimes a chemotherapy (taxane), for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the combination is safe and can shrink or control tumors. About 65 adults with various advanced cancers will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Asan Medical Center

    NOT_YET_RECRUITING

    Seoul, 05505, South Korea

  • PASO Medical

    NOT_YET_RECRUITING

    Frankston, Victoria, 3199, Australia

  • Samsung Medical Center

    NOT_YET_RECRUITING

    Seoul, 06351, South Korea

  • Seoul National University Bundang Hospital

    RECRUITING

    Seongnam, 13620, South Korea

  • Seoul National University Hospital

    RECRUITING

    Seoul, 03080, South Korea

  • UH Cleveland Medical Center

    NOT_YET_RECRUITING

    Cleveland, Ohio, 44106, United States

Conditions

Explore the condition pages connected to this study.